Friday, November 24, 2006 6:30:00 AM PDT | VentureDeal Staff
LEXINGTON, MA - Synta Pharmaceuticals Corp. is planning to float its shares in the public markets, according to a recent filing with the SEC.The filing suggests the company will seek up to $115 million, nearly 18 months after pulling a previous IPO due to uncertain market conditions.The company has one cancer drug that is near late-stage trials and several others that are in mid-stage trials for Crohn's disease and cancer.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
Founded in 2006, VentureDeal is a database that provides the latest information about venture capital firms, venture-backed technology companies and transactions throughout North America.
Learn More »
Email Sign Up
© 2016 VentureDeal, Inc., Menlo Park, CA. All Rights Reserved.